GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (7)
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 79, No. 13_Supplement ( 2019-07-01), p. 4996-4996
    Abstract: Exciting breakthroughs in tumor immunology have led to the discovery and development of several promising immunotherapeutic strategies for cancer patients. Thus far, immune checkpoint inhibitors have been the most encouraging for solid tumors, however, treatment responses are observed in only a subset of patients and these appear to be primarily dependent on a tumor’s baseline immune profile. Additionally, tumors respond differently to immunotherapy and criteria to assess treatment responses are still being refined. We have identified a set of immune-related genes and developed a scoring system to profile the tumor’s immune status and assess immunological responses. In this study, we used a qRT-PCR-based approach to assess this panel and determine baseline tumor immune-profiles in an immunocompetent mouse model of Pten-null prostate cancer. We also assessed and compared tumor immune responses following androgen withdrawal (via surgical castration) and anti-PD-L1 immune checkpoint blockade. A total of 96 genes were selected for this focused panel which consisted of cell-type, immuno-responsive and housekeeping control genes. Core modules were designated based on functional gene associations which included antigen presentation, tumor inflammation, effector cells, immunomodulatory cells, immunosuppressive signaling and immune checkpoints. Core modules were further subdivided in to appropriately relevant sub-modules. A score for each submodule was calculated and a weighed score was then assigned for each core module. Tumor immunophenotypes based on core and sub-core immune scores (IS) were corroborated with immunohistochemical and/or flow cytometric analyses. Mouse castration-naïve prostate tumors exhibited low scores indicating a ‘”cold tumor” phenotype with little variation between individual mice. Androgen withdrawal induced cancer cell death in these tumors that in turn promoted immune cell infiltration. Core and sub-core IS of individual mice identified varied signatures reminiscent of immune excluded and inflamed “hot tumor” phenotypes. Short-term treatment with anti-PD-L1 blockade (clone D265A, mouse/IgG1 kappa) elicited an increased immune response signature in tumors from surgically castrated mice, but not in tumors from intact mice. Notably, discernable differences were noted among individual responders supporting the notion that responses to immune checkpoint may indeed be dependent on baseline tumor immune-profiles. In summary, androgen withdrawal appears to promote a “hotter” immunological phenotype in this model of prostate cancer, that is increased further by PD-L1 inhibition. Moreover, this investigation provides proof of concept evidence for a qRT-PCR-based biomarker approach for immuno-oncology. Citation Format: Marco A. De Velasco, Yurie Kura, Noriko Sato, Naomi Ando, Kazuko Sakai, Yasunori Mori, Barry R. Davies, Masahiro Nozawa, Kazuhiro Yoshimura, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura. A real-time PCR-based approach to quantitatively assess tumor immune profiles and immune responses [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4996.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2019
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 7_Supplement ( 2023-04-04), p. 640-640
    Abstract: Studies suggest that certain immune-mediated diseases may be associated with cancer risk beyond local organs. Prolonged systemic inflammation from inflammatory bowel diseases such as ulcerative colitis (UC) and Crohn’s disease (CD) pose a greater risk to colorectal cancer (CRC) and accumulating data suggests that prostate cancer (PCa) risk is higher in patients with UC but not CD and that patients with PCa may be at a greater risk for CRC. A better understanding of the biological interactions between these conditions could have important implications for cancer screening, detection, and prevention in high-risk populations. However, data to establish the relationships and relative contributions of these diseases are lacking. Here, we explored these relationships using preclinical mouse models of dextran sulfate sodium (DSS)-induced colitis (DSS-UC) and DSS/azoxymethane (AOM)-induced CRC (DSS/AOM-CRC) in young and aged healthy wildtype mice and transgenic mice harboring Pten-deficient PCa. In the DSS/AOM-CRC model, aged PCa-bearing conditional Pten-knockout (KO) mice experienced poorer overall survival compared to age-matched wildtype (WT) without PCa because of CRC. DSS/AOM-CRC incidence was not affected by the presence of PCa, however tumor burden was higher in KO mice compared to WT and in KO mice, DSS/AOM-CRC accelerated PCa growth and progression. Prostates from WT DSS/AOM-CRC mice showed higher incidence of hyperplasia and greater myeloid cell infiltration compared to healthy controls. Systemic changes associated with DSS/AOM-CRC in both WT and KO mice included splenomegaly, lymphadenopathy, and immune cell composition. The impact of DSS-UC was investigated conditional Pten/Trp53-double knockout (DKO) mice with DDS only treatments starting at an age prior to the development of PCa. In this setting, cycling DSS led to the development of UC after 10 weeks of treatment and accelerated prostate tumor development characterized by high grade prostatic intraepithelial neoplasia (PIN) grade dysplasia and increased cell proliferation. Prostate tumors from mice with DSS-UC exhibited an altered tumor immune microenvironment characterized by a higher degree of inflammatory cell infiltrate. Changes in immune cell composition were also observed in peripheral blood and secondary lymphoid organs. These preclinical models recapitulated disease relationships observed in humans and provide a platform to further investigate biological mechanisms and therapeutic interventions. Citation Format: Marco A. De Velasco, Yurie Kura, Kazuko Sakai, Naomi Ando, Noriko Sako, Kazutoshi Fujita, Shogo Adomi, Eri Banno, Yasunori Mori, Takafumi Minami, Masahiro Nozawa, Kazuhiro Yoshimura, Kazuto Nishio, Hirotsugu Uemura. Exploring the relationships between prostate cancer, colorectal cancer, and ulcerative colitis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 640.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 7_Supplement ( 2023-04-04), p. 3044-3044
    Abstract: Gut microbes are intricately involved in maintaining normal physiology and homeostasis and have become a major area of study to determine their relevance in human disease. In cancer, alterations to gut microbiota has been associated to resistance to chemo- and immuno-therapy, whereas supplementation with specific taxa improves antitumor treatment responses. Mouse models have been essential to study disease biology and drug discovery. However, mice are fundamentally quite different from humans, thus, questions have arisen regarding their utility as pertinent tools to study microbial influences and their impact on human disease. To address these questions, we have performed a cross-species comparative analysis of the fecal microbiota from a human cohort of prostate cancer patients and a preclinical mouse model of prostate cancer. Microbiota composition was determined by 16s RNA gene sequencing on stool samples from tumor-bearing prostate-specific conditional Pten-knockout and disease-free wildtype mice and 16s RNA gene sequencing data from a human cohort of patients with suspected prostate cancer was used. Human cases were assigned to no cancer and cancer groups based on diagnosis from prostate biopsy and as low-risk (negative biopsy of Gleason grade & lt;3) or high-risk (Gleason grade ≥3). Community composition differed significantly between stool samples of cancer and disease-free individuals in mice but not humans. Operational taxonomic units (OTUs) corresponding to taxa associated with cancer in both mice and humans included Odoribacter spp. and Desulfovibrio spp. Comparing the profiles predicted with Tax4Fun revealed KEGG metabolic pathways associated prostate cancer. Pathways enriched in cancer bearing-mice and that are also associated in patients with prostate cancer included folate biosynthesis, biotin metabolism and ubiquinone & other terpenoid-quinone biosynthesis. Carbon metabolism was a pathway discordant between high-risk prostate cancer patients and cancer bearing mice. Although the basal composition of gut microbes differed between humans and mice, the functional microbiome showed greater similarities. Our cross-species comparative analysis shows that gut microbial dysbiosis is connected to prostate cancer provides additional insights into the biological processes involved. This study provides additional data that may help to bridge the gap between humans and mice. Citation Format: Chisato Wakamori, Marco A. De Velasco, Yurie Kura, Naomi Ando, Noriko Sako, Kazutoshi Fujita, Kazuko Sakai, Makoto Matsushita, Eri Banno, Yasunori Mori, Masahiro Nozawa, Mitsuhisa Nishimoto, Kazuhiro Yoshimura, Norio Nonomura, Kazuto Nishio, Hirotsugu Uemura. Integrative gut microbiome analysis of human and mouse prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3044.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 76, No. 14_Supplement ( 2016-07-15), p. 4315-4315
    Abstract: Prostate cancer is a highly heterogeneous disease and evidence indicates that lifestyle and environmental factors can contribute to cancer-related deaths. Accumulating data also suggests that increased dietary fat consumption may promote and increase the risk of prostate cancer-related morbidity and mortality. However, data between studies is inconsistent and a direct link between increased consumption of dietary fat and the promotion of prostate cancer remains unclear. Here, we present our findings from a preclinical study of increased dietary fat consumption and its effects on prostate tumor growth and progression using genetically engineered mouse models of prostate cancer. We determined the effects of a high fat diet on tumor cell proliferation and apoptosis in vivo using a well-established mouse model of prostate cancer. Twenty-week-old mice, with conditional biallelic deletion of PTEN, harboring castration-naïve or castration-resistant prostate tumors were randomized and assigned to a standard laboratory diet (4% fat) or a high-fat diet (HFD, 13.6% fat) for 8 weeks. In both tumor models, mice fed a HFD had increased expression levels of proteins associated with proliferation and decreased levels of apoptosis markers. To determine the long term effects of a HFD, we used a mouse model of advanced prostate cancer. Mice with concomitant inactivation of PTEN and p53 develop tumors that progress quickly and are characterized with increased metastatic development and decreased survival compared to PTEN knockout mice. PTEN/p53 double knockout mice were randomized and assigned to control or HFD experimental groups after weaning. Our findings revealed that mice fed a HFD resulted in obesity that led to decreased progression-free survival and overall survival rates compared to mice fed a standard diet. Our results provide evidence to support the effects of high dietary fat consumption and increased prostate cancer risk, and provide a platform to investigate chemoprevention strategies. Citation Format: Marco A. De Velasco, Yurie Kura, Yuji Hatanaka, Takashi Oki, Yutaka Yamamoto, Koichi Sugimoto, Yasunori Mori, Kazuhiro Yoshimura, Masahiro Nozawa, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura. Effects of increased dietary fat consumption on prostate cancer progression in genetically engineered mice. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4315.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2016
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 79, No. 13_Supplement ( 2019-07-01), p. 1613-1613
    Abstract: Epidemiological data has shown that dietary practices can greatly influence cancer rates. Men in East Asian countries, men have significantly lower prostate cancer rates compared to their counterparts the US and Europe. Soybeans are a versatile and rich source of protein and its products constitute a rich portion of Asian diets. Recent interest in healthy eating has expanded the consumption of soy products which also provide a rich source of naturally occurring isoflavones and 17β-estradiol. In this study, we used roasted soybean flour (kinako), which contains high levels isoflavones glycosides and estradiol, as dietary soy source to determine the influence of isoflavones rich diets on prostate cancer. Six-week old conditional Pten/Trp53 double knockout mice were randomized and fed plain AIN-93M (Control) diets or a diets supplemented with kinako ad libitum. Concentrations of kinako were adjusted to for daily intakes of aglycone isoflavones (genistein, daidzein, and glycetein) of 400 (LDI) and 800 (HDI) mg. Mice were sacrificed at 16 and 20 weeks (n=6 mice/group) or maintained for survival assessment (n=8 mice/group). Dietary intake of kinako-supplemented diets did not influence the onset of prostatic intraepithelial neoplasia or tumor burden at the early stages. However, tumors from mice fed the HDI diet experienced reduced tumor proliferation rates. Moreover, mice fed LDI and HDI diets showed reduced androgen receptor (AR) protein expression levels as well as mRNA levels for the AR target genes Fkbp5, Nk3x3.1 and Timp4. Interestingly, mice on the LDI diet, but not the HDI, experienced longer times to disease progression (median times 264, 299 and 250 days for Control, LDI and HDI, respectively, P=0.663), tumor doubling (median times 14, 27 and 14 days for Control, LDI and HDI, respectively, P=0.083), cumulative survival (median times 292, 348 and 320 days for Control, LDI and HDI, respectively, P=0.199), and overall survival times (median times 28, 43 and 35 days for Control, LDI and HDI, respectively, P=0.324). The metastatic incidence was 33%, 14% and 14% for Control, LDI and HDI groups, respectively, P=0.631. We also investigated whether dietary intervention with kinako would impact previously stablished tumors. For this we fed kinako supplemented diets to conditional Pten-knockout mice with established tumors but no changes were observed in tumor burden, proliferation, apoptosis and AR activity. Together our data shows that long-term continuous ingestion of a diet rich in isoflavones may be necessary in order suppress tumor growth. Interestingly, this protective effect appears to be lost with high-doses of the dietary isoflavones. Further studies will need to be performed in order to decipher complex dynamic interplay between survival pathways isoflavones chemoprevention. Citation Format: Yasunori Mori, Marco A. De Velasco, Yurie Kura, Eri Banno, Naomi Ando, Noriko Sato, Masahiro Nozawa, Kazuhiro Yoshimura, Kazuko Sakai, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura. Dietary isoflavone decreases prostate cancer progression and improves survival in conditional Pten/Trp53-deficient mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1613.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2019
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 7_Supplement ( 2023-04-04), p. 1838-1838
    Abstract: Prostate cancer is notoriously resistant to immune checkpoint blockade (ICB) immunotherapy due to its immunosuppressive tumor microenvironment (TME). Thus, reprograming the TME could improve antitumor immune responses to ICB. Curcumin is a naturally derived compound with chemopreventive and immunomodulatory properties, however, its potential is limited due to its poor bioavailability. Curcumin monoglucuronide (CMG) is a water-soluble prodrug with improved bioavailability over free-form of curcumin. We previously demonstrated the immunomodulatory potential of CMG in a transgenic mouse model of Pten-null prostate cancer, here we examine its ability to improve the antitumor immune response to ICB of the programmed death cell protein 1 (PD1). Thirty-two-week-old PSA-Cre/Ptenf/f knockout (KO) mice were treated with anti-PD1 (aPD1) blocking antibody, CMG alone and in combination for 17 days weeks. Antitumor responses were determined by prostate weight, histology, and cancer proliferation and apoptosis by quantitative immunohistochemistry (qIHC). Immune responses were assessed by focused panel qRT-PCR, qIHC, and flow cytometric (FC) analysis. Systemic immune responses were assessed by FC analysis if peripheral blood and secondary lymphoid organs. Short-term dosing of aPD1 alone or in combination did not affect tumor burden as assessed by a reduction of prostate weight, however, histological analysis revealed that mice treated with CMG/aPD1 exhibited an increase in the proportion of edematous dilated glands and a non-significant reduction of solid tumor. Mice treated with CMG/aPD1 showed a significant reduction of s cancer cell proliferation (Ki67) and mice treated with CMG/aPD1 showed a 1.5-fold increase in cancer cell apoptosis. Gene expression analysis indicated upregulation of genes associated with NKT, NK and dendritic cells with combination therapy. FC and qIHC analysis indicated that T cell activation and T cell cytotoxicity was improved when CMG was administered together with aPD-1. Systemically, treatments with PD-L1 alone or in combination with CMG were associated with increased circulating myeloid-derived suppressor cells (MDSCs). Our findings provide preclinical evidence for the antitumor and immune modulatory activity of CMG in mouse Pten-deficient prostate cancer and supports further study to evaluate long-term therapy and explore additional treatment combinations. Citation Format: Yurie Kura, Marco A. De Velasco, Kazuko Sakai, Naomi Ando, Noriko Sako, Kazutoshi Fujita, Eri Banno, Yasunori Mori, Mamoru Hashimoto, Masahiro Nozawa, Kazuhiro Yoshimura, Hideaki Kakeya, Kazuto Nishio, Hirotsugu Uemura. Immunomodulatory effects of curcumin monoglucuronide on PD1 immune checkpoint blockade in mouse Pten-null prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1838.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 7_Supplement ( 2023-04-04), p. 2877-2877
    Abstract: Myeloid-derived suppressor cells (MDSCs) are a heterogenous population of immature immune cells that expand during cancer and can induce potent immune suppression. These cells play critical roles in supporting tumor growth and progression and their induction has been associated with the inactivation of PTEN. To date, few therapies targeting these cells are available which is partly due to their increasingly complex nature and context-dependent functions. Moreover, there is no clear definition to identify these cells. Enhancing our understanding of this cell population will aid in developing more effective cancer therapies. Here, we used gene expression profiling, flow cytometry, and quantitative immunohistochemistry to characterize tumor-infiltrating and circulating MDSCs in prostate carcinogenesis and progression in transgenic mouse models of prostate cancer driven by the conditional inactivation of Pten and Trp53. Transcriptomic profiling revealed enrichment of various myeloid-derived cell signatures in the early stages of prostate cancer including MDSCs, macrophages, and neutrophils. Flow cytometric analysis confirmed the increased infiltration of CD11b+/Ly6G+ (polymorphonuclear MDSCs (pMDSCs)) and CD11b+/Ly6C+ (monocytic MDSCs (mMDSCs)) cells in prostate tumors. The temporal dynamics of tumor-infiltrating myeloid cells were further profiled and showed that pMDSC and mMDSC abundances were 1.6 and 5.7-fold higher, respectively, in older mice with late-stage locally invasive adenocarcinomas (AdCa) compared to younger mice with early-stage prostatic intraepithelial neoplasia (PIN). In both instances, pMDSCs comprised most of the leukocyte infiltrate, however, mMDSCs tended to be positively correlated with tumor burden in AdCa but not PIN. In peripheral blood, CD44+/CD62L+ immature neutrophils were associated with high tumor burden in aged mice. Treatments targeting the androgen receptor (AR) signaling further exacerbated pMDSC infiltration in tumors and was associated with resistance to second androgen receptor-targeted agent (ARTA) therapy in a model of castration resistant prostate cancer. Our findings indicate that MDSCs are a prominent population in Pten-null prostate cancer and are implicated with resistance to prostate cancer treatment. MDSCs constitute a potentially targetable population and these models serve as viable platforms to further investigate their biological activity and further evaluate novel MDSC-directed therapies. Citation Format: Marco A. De Velasco, Yurie Kura, Noriko Sako, Naomi Ando, Kazuko Sakai, Eri Banno, Shogo Adomi, Mitsuhisa Nishimoto, Takafumi Minami, Yasunori Mori, Kazutoshi Fujita, Masahiro Nozawa Nozawa, Kazuhiro Yoshimura, Kazuto Nishio, Hirotsugu Uemura. Profiling of myeloid-derived suppressor cells in Pten-deficient in prostate cancer progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2877.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...